The Glucose Transporter 5 Enhances CAR-T Cell Metabolic Function and Anti-tumour Durability

The Glucose Transporter 5 Enhances CAR-T Cell Metabolic Function and Anti-tumour Durability | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article The Glucose Transporter 5 Enhances CAR-T Cell Metabolic Function and Anti-tumour Durability Roddy O'Connor, Bakir Valentić, Andre Kelly, Alexander Shestov, and 11 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4342820/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Activated T cells undergo a metabolic shift to aerobic glycolysis to support the energetic demands of proliferation, differentiation, and cytolytic function. Transmembrane glucose flux is facilitated by glucose transporters (GLUT) that play a vital role in T cell metabolic reprogramming and anti-tumour function. GLUT isoforms are regulated at the level of expression and subcellular distribution. GLUTs also display preferential selectivity for carbohydrate macronutrients including glucose, galactose, and fructose. GLUT5, which selectively transports fructose over glucose, has never been explored as a genetic engineering strategy to enhance CAR-T cells in fructose-rich tumour environments. Fructose levels are significantly elevated in the bone marrow and the plasma of acute myeloid leukaemia (AML) patients. Here, we demonstrate that the expression of wild-type GLUT5 restores T cell metabolic fitness in glucose-free, high fructose conditions. We find that fructose supports maximal glycolytic capacity and ATP replenishment rates in GLUT5-expressing T cells. Using steady state tracer technology, we show that 13C6 fructose supports glycolytic reprogramming and TCA anaplerosis in CAR-T cells undergoing log phase expansion. In cytotoxicity assays, GLUT5 rescues T cell cytolytic function in glucose-free medium. The fructose/GLUT5 metabolic axis also supports maximal migratory velocity, which provides mechanistic insight into why GLUT5-expressing CAR-Ts have superior effector function as they undergo “hit-and-run” serial killing. These findings translate to superior anti-tumour function in a xenograft model of AML. In fact, we found that GLUT5 enhances CAR-T cell anti-tumour function in vivo without any need for fructose intervention. Accordingly, we hypothesize that GLUT5 is sufficient to enhance CAR-T resilience by increasing the cells’ competitiveness for glucose at physiologic metabolite levels. Our findings have immediate translational relevance by providing the first evidence that GLUT5 confers a competitive edge in a fructose-enriched milieu, and is a novel approach to overcome glucose depletion in hostile tumour microenvironments (TMEs). Biological sciences/Cancer/Cancer therapy/Cancer immunotherapy Biological sciences/Biochemistry/Metabolomics Full Text Additional Declarations There is NO Competing Interest. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4342820","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":299050217,"identity":"2bbf97a4-9fd9-4ce1-a299-7047fbf7b769","order_by":0,"name":"Roddy O'Connor","email":"data:image/png;base64,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","orcid":"https://orcid.org/0000-0001-5645-4544","institution":"Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA","correspondingAuthor":true,"prefix":"","firstName":"Roddy","middleName":"","lastName":"O'Connor","suffix":""},{"id":299050220,"identity":"e39eb3bb-7136-4f75-a13f-60e979857f5c","order_by":1,"name":"Bakir Valentić","email":"","orcid":"https://orcid.org/0009-0007-5253-0010","institution":"Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA","correspondingAuthor":false,"prefix":"","firstName":"Bakir","middleName":"","lastName":"Valentić","suffix":""},{"id":299050223,"identity":"9b2973a3-92fc-4d35-8329-cfd113e2e127","order_by":2,"name":"Andre Kelly","email":"","orcid":"","institution":"Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA","correspondingAuthor":false,"prefix":"","firstName":"Andre","middleName":"","lastName":"Kelly","suffix":""},{"id":299050226,"identity":"8c5201b2-bdb7-4cf3-8156-e0afe10af2c4","order_by":3,"name":"Alexander Shestov","email":"","orcid":"","institution":"Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA","correspondingAuthor":false,"prefix":"","firstName":"Alexander","middleName":"","lastName":"Shestov","suffix":""},{"id":299050229,"identity":"35ed0306-e406-459a-be02-3a13e02fb32a","order_by":4,"name":"Zhiyang Gan","email":"","orcid":"","institution":"Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA","correspondingAuthor":false,"prefix":"","firstName":"Zhiyang","middleName":"","lastName":"Gan","suffix":""},{"id":299050232,"identity":"2e4fc315-12db-467f-8d67-b8eaba6ad265","order_by":5,"name":"Feng Shen","email":"","orcid":"","institution":"Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA","correspondingAuthor":false,"prefix":"","firstName":"Feng","middleName":"","lastName":"Shen","suffix":""},{"id":299050235,"identity":"bc0983db-ec19-4830-815c-5ea80a651283","order_by":6,"name":"Adam Chatoff","email":"","orcid":"https://orcid.org/0000-0002-7954-9527","institution":"Aging + Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA","correspondingAuthor":false,"prefix":"","firstName":"Adam","middleName":"","lastName":"Chatoff","suffix":""},{"id":299050238,"identity":"8e7f1738-dfea-433d-bc69-e22d8c773adb","order_by":7,"name":"Alison Jaccard","email":"","orcid":"","institution":"Aging + Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA","correspondingAuthor":false,"prefix":"","firstName":"Alison","middleName":"","lastName":"Jaccard","suffix":""},{"id":299050241,"identity":"f2fd5474-fe81-4c3a-a098-20c2888b0040","order_by":8,"name":"Claudia Crispim","email":"","orcid":"","institution":"Aging + Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA","correspondingAuthor":false,"prefix":"","firstName":"Claudia","middleName":"","lastName":"Crispim","suffix":""},{"id":299050243,"identity":"f69d5fcc-dc99-4d6b-bc7a-ae4bd5472b5e","order_by":9,"name":"John Scholler","email":"","orcid":"","institution":"University of Pennsylvania","correspondingAuthor":false,"prefix":"","firstName":"John","middleName":"","lastName":"Scholler","suffix":""},{"id":299050245,"identity":"7b8b64bf-a6da-4666-8231-f03e802a2dfd","order_by":10,"name":"Simon Heeke","email":"","orcid":"https://orcid.org/0000-0002-5916-534X","institution":"The University of Texas MD Anderson Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Simon","middleName":"","lastName":"Heeke","suffix":""},{"id":299050247,"identity":"395c0973-045e-449f-83a7-581242d08189","order_by":11,"name":"Nathaniel Snyder","email":"","orcid":"https://orcid.org/0000-0001-5643-8747","institution":"Temple University","correspondingAuthor":false,"prefix":"","firstName":"Nathaniel","middleName":"","lastName":"Snyder","suffix":""},{"id":299050249,"identity":"008b5813-bbb8-4a89-9f51-56a6440b7b1e","order_by":12,"name":"Saba Ghassemi","email":"","orcid":"","institution":"Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA","correspondingAuthor":false,"prefix":"","firstName":"Saba","middleName":"","lastName":"Ghassemi","suffix":""},{"id":299050251,"identity":"02feaf07-2452-42c0-bdb5-243ae92a4dbe","order_by":13,"name":"Nicholas Jones","email":"","orcid":"https://orcid.org/0000-0003-4846-5117","institution":"Swansea University Medical School","correspondingAuthor":false,"prefix":"","firstName":"Nicholas","middleName":"","lastName":"Jones","suffix":""},{"id":299050253,"identity":"0f496456-73d7-4e94-ad46-5e3283b653a2","order_by":14,"name":"Saar Gill","email":"","orcid":"https://orcid.org/0000-0001-7946-7778","institution":"University of Pennsylvania","correspondingAuthor":false,"prefix":"","firstName":"Saar","middleName":"","lastName":"Gill","suffix":""}],"badges":[],"createdAt":"2024-04-29 12:21:59","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4342820/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4342820/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":73040607,"identity":"905c6419-fa80-492f-b984-9e35879b517f","added_by":"auto","created_at":"2025-01-06 07:48:22","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1527574,"visible":true,"origin":"","legend":"","description":"","filename":"BValenticG504292024.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4342820/v1_covered_29395090-171c-483c-a394-a1b7bc83e8c0.pdf"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e Competing Interest.","formattedTitle":"The Glucose Transporter 5 Enhances CAR-T Cell Metabolic Function and Anti-tumour Durability","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-4342820/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4342820/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"Activated T cells undergo a metabolic shift to aerobic glycolysis to support the energetic demands of proliferation, differentiation, and cytolytic function. Transmembrane glucose flux is facilitated by glucose transporters (GLUT) that play a vital role in T cell metabolic reprogramming and anti-tumour function. GLUT isoforms are regulated at the level of expression and subcellular distribution. GLUTs also display preferential selectivity for carbohydrate macronutrients including glucose, galactose, and fructose. GLUT5, which selectively transports fructose over glucose, has never been explored as a genetic engineering strategy to enhance CAR-T cells in fructose-rich tumour environments. Fructose levels are significantly elevated in the bone marrow and the plasma of acute myeloid leukaemia (AML) patients. Here, we demonstrate that the expression of wild-type GLUT5 restores T cell metabolic fitness in glucose-free, high fructose conditions. We find that fructose supports maximal glycolytic capacity and ATP replenishment rates in GLUT5-expressing T cells. Using steady state tracer technology, we show that 13C6 fructose supports glycolytic reprogramming and TCA anaplerosis in CAR-T cells undergoing log phase expansion. In cytotoxicity assays, GLUT5 rescues T cell cytolytic function in glucose-free medium. The fructose/GLUT5 metabolic axis also supports maximal migratory velocity, which provides mechanistic insight into why GLUT5-expressing CAR-Ts have superior effector function as they undergo “hit-and-run” serial killing. These findings translate to superior anti-tumour function in a xenograft model of AML. In fact, we found that GLUT5 enhances CAR-T cell anti-tumour function in vivo without any need for fructose intervention. Accordingly, we hypothesize that GLUT5 is sufficient to enhance CAR-T resilience by increasing the cells’ competitiveness for glucose at physiologic metabolite levels. Our findings have immediate translational relevance by providing the first evidence that GLUT5 confers a competitive edge in a fructose-enriched milieu, and is a novel approach to overcome glucose depletion in hostile tumour microenvironments (TMEs).","manuscriptTitle":"The Glucose Transporter 5 Enhances CAR-T Cell Metabolic Function and Anti-tumour Durability","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-05-07 01:57:36","doi":"10.21203/rs.3.rs-4342820/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"5df691b1-b6bd-48ed-8787-47ba7fccf0c7","owner":[],"postedDate":"May 7th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":31547598,"name":"Biological sciences/Cancer/Cancer therapy/Cancer immunotherapy"},{"id":31547599,"name":"Biological sciences/Biochemistry/Metabolomics"}],"tags":[],"updatedAt":"2025-01-06T07:40:14+00:00","versionOfRecord":[],"versionCreatedAt":"2024-05-07 01:57:36","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4342820","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4342820","identity":"rs-4342820","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}